Crossmark

606 Pharmacodynamic activity of CX-801, a masked IFNα2b PROBODY® cytokine, in patients with advanced melanoma

Crossref DOI link: https://doi.org/10.1136/jitc-2025-SITC2025.0606

Published Online: 2025-11-04

Published Print: 2025-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Povinelli, Benjamin

Tsai, Yihsuan

Dhar, Kakali

Leonowens, Cathrine

Johnston, Stuart H

Vasiljeva, Olga

Paidhungat, Madan

Chu, Yu-Waye

Belvin, Marcia

Kirkwood, John M

Najjar, Yana G

Vainorius, Monika

Daniel, Dylan
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct06462794 at ClinicalTrials.gov

Documents that mention this clinical trial

606 Pharmacodynamic activity of CX-801, a masked IFNα2b PROBODY® cytokine, in patients with advanced melanoma
https://doi.org/10.1136/jitc-2025-sitc2025.0606

Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade
https://doi.org/10.1136/jitc-2024-010566
License Information

License valid from 2025-10-31